in an oral presentation and a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. The ...

Veteran teachers are no strangers to the disruptions caused by new technologies. AI is the latest in a long line of ...

Presentation operator Ladies and gentlemen, good day and welcome to the Colgate Pamela India Limited analyst conference call for the financial year 2024 25. As a reminder, all participant lines will ...

Thirty-some years later, the amateur climate scientist made the remarkable discovery that when sunlight shines on carbon dioxide in a closed container—our atmosphere, for example—heat ... an 1857 ...

Just 45 miles north of Tulsa in the rolling hills of northeastern Oklahoma, Bartlesville stands as a testament to what happens when oil wealth, architectural vision, and good old-fashioned Midwestern ...

Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

Merely click on TED and no fewer than 5,000 current presentation topics appear. One could see them live or view them online. Perhaps as a result of TED, more organizations now require oral ...

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A ...